IHAM
CYTK icon

Integral Health Asset Management’s Cytokinetics CYTK Stock Holding History

Integral Health Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105M Buy
1,600,000
+200,000
+14% +$12.7M 5.04% 3
2025
Q4 		$89M Hold
1,400,000
– – 4.42% 4
2025
Q3 		$76.9M Buy
1,400,000
+400,000
+40% +$16.5M 5.21% 2
2025
Q2 		$33M Sell
1,000,000
-100,000
-9% -$3.48M 3.02% 6
2025
Q1 		$44.2M Buy
1,100,000
+100,000
+10% +$4.6M 4.7% 3
2024
Q4 		$47M Buy
1,000,000
+250,000
+33% +$13M 4.01% 5
2024
Q3 		$39.6M Sell
750,000
-250,000
-25% -$13.9M 4.46% 4
2024
Q2 		$54.2M Buy
1,000,000
+550,000
+122% +$33.2M 5.15% 3
2024
Q1 		$31.5M Buy
450,000
+250,000
+125% +$19.3M 2.93% 5
2023
Q4 		$16.7M Sell
200,000
-600,000
-75% -$21.7M 2.27% 10
2023
Q3 		$23.6M Buy
800,000
+150,000
+23% +$5M 3.26% 5
2023
Q2 		$21.2M Buy
650,000
+50,000
+8% +$1.85M 2.63% 7
2023
Q1 		$21.1M Buy
600,000
+200,000
+50% +$8.16M 4.25% 2
2022
Q4 		$18.3M Buy
400,000
+50,000
+14% +$2.15M 3.85% 2
2022
Q3 		$17M Sell
350,000
-175,000
-33% -$8.42M 3.29% 5
2022
Q2 		$20.6M Buy
525,000
+55,000
+12% +$2.21M 4.24% 4
2022
Q1 		$17.3M Buy
470,000
+145,000
+45% +$5.15M 4.5% 2
2021
Q4 		$14.8M Hold
325,000
– – 4.1% 3
2021
Q3 		$11.6M Sell
325,000
-375,000
-54% -$11M 3.34% 5
2021
Q2 		$13.9M Hold
700,000
– – 3.81% 4
2021
Q1 		$16.3M Buy
700,000
+175,000
+33% +$3.74M 4.65% 2
2020
Q4 		$10.9M Buy
525,000
+325,000
+163% +$5.94M 3.25% 8
2020
Q3 		$4.33M Sell
200,000
-140,000
-41% -$3.27M 1.32% 26
2020
Q2 		$8.01M Buy
340,000
+20,000
+6% +$375K 2.4% 14
2020
Q1 		$3.77M Buy
+320,000
New +$4.08M 1.66% 24

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Integral Health Asset Management's CYTK Position: Q1 2026 in Review

Integral Health Asset Management increased its Cytokinetics (CYTK) stake by 14% in Q1 2026, buying an estimated $12.7M and bringing the position to 1,600,000 shares worth $105M. The position accounts for 5.04% of the portfolio, ranked #3.

Integral Health Asset Management first reported a position in CYTK in Q1 2020 and has held it in 25 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Integral Health Asset Management held 1,600,000 shares of Cytokinetics worth $105M as of Q1 2026.
  • Integral Health Asset Management bought 200,000 Cytokinetics shares in Q1 2026, an estimated $12.7M.
  • Cytokinetics made up 5.04% of Integral Health Asset Management's portfolio in Q1 2026, its #3 holding.
  • Integral Health Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 25 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.